ACRS

MKT CAP:$520M

Aclaris Therapeutics, Inc.

Market Cap

$520M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$4.55+$1.67 (+57.99%)

Apr 23, 2026

Company Details

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The ...

CEO

Neal S. Walker

IPO Date

Oct 6, 2015

Website

www.aclaristx.com

Key Metrics TTM

Revenue

$8M

-58.2% YoY

Net Income

-$65M

EPS (Diluted)

-$0.53

Free Cash Flow

-$47M

Revenue / Share

$0.06

Gross Margin

73.3%

Operating Margin

-975.9%

Net Margin

-829.6%

FCF Margin

-602.6%

P/S

66.5x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$8M-58.2%EPS -$0.53

Q4 2025

Feb 26, 2026

$1M-85.9%EPS -$0.16

Q3 2025

Nov 6, 2025

$3M-24.1%EPS -$0.12

Q2 2025

Aug 7, 2025

$2M-35.8%EPS -$0.13

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$1M	$298.0K	-$19M
Q2 22	$2M	$460.0K	-$21M
Q3 22	$19M	$11M	-$21M
Q4 22	$8M	$6M	-$29M
Q1 23	$3M	$659.0K	-$30M
Q2 23	$2M	$277.0K	-$32M
Q3 23	$9M	$1M	-$32M
Q4 23	$18M	$11M	-$4M
Q1 24	$2M	$558.0K	-$19M
Q2 24	$3M	$857.0K	-$13M
Q3 24	$4M	$2M	-$10M
Q4 24	$9M	-$90.0K	-$100M
Q1 25	$1M	$949.0K	-$18M
Q2 25	$2M	-$73.0K	-$18M
Q3 25	$3M	$3M	-$17M
Q4 25	$1M	$2M	-$23M

Valuation

Quarter	P/S	P/E
Q1 22	168.3x	—
Q2 22	162.3x	—
Q3 22	43.6x	—
Q4 22	36.7x	—
Q1 23	19.8x	—
Q2 23	23.8x	—
Q3 23	21.5x	—
Q4 23	2.7x	—
Q1 24	2.9x	—
Q2 24	2.6x	—
Q3 24	3.3x	—
Q4 24	10.2x	—
Q1 25	6.7x	—
Q2 25	10.4x	—
Q3 25	15.0x	—
Q4 25	47.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$21M	-$21M
Q2 22	-$20M	-$20M
Q3 22	-$8M	-$8M
Q4 22	-$19M	-$19M
Q1 23	-$26M	-$27M
Q2 23	-$21M	-$21M
Q3 23	-$25M	-$25M
Q4 23	-$7M	-$7M
Q1 24	-$21M	-$21M
Q2 24	-$12M	-$12M
Q3 24	$22M	$22M
Q4 24	-$9M	-$45M
Q1 25	-$13M	-$13M
Q2 25	-$10M	-$10M
Q3 25	-$11M	-$11M
Q4 25	-$13M	-$13M

Capital Expenditures

Quarter	CapEx
Q1 22	$164.0K
Q2 22	$186.0K
Q3 22	$150.0K
Q4 22	$105.0K
Q1 23	$553.0K
Q2 23	$231.0K
Q3 23	$84.0K
Q4 23	$441.0K
Q1 24	$135.0K
Q2 24	$14.0K
Q3 24	$0
Q4 24	$36M
Q1 25	$43.0K
Q2 25	$21.0K
Q3 25	$23.0K
Q4 25	$44.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-18.2%	-32.8%
Q2 22	-16.2%	+13.6%
Q3 22	+1046.4%	+81.7%
Q4 22	+416.5%	+51.0%
Q1 23	+74.0%	+59.4%
Q2 23	+22.3%	+49.6%
Q3 23	-51.2%	+2.4%
Q4 23	+126.6%	-41.3%
Q1 24	-5.1%	-34.3%
Q2 24	+48.0%	-53.6%
Q3 24	-53.2%	-63.7%
Q4 24	-47.6%	+403.7%
Q1 25	-39.3%	-8.4%
Q2 25	-35.8%	+29.2%
Q3 25	-24.1%	+38.0%
Q4 25	-85.9%	-77.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	161.5%
Q2 22	$4M	241.6%
Q3 22	$4M	22.0%
Q4 22	$5M	62.1%
Q1 23	$7M	269.2%
Q2 23	$7M	349.0%
Q3 23	$6M	64.1%
Q4 23	$1M	7.2%
Q1 24	$2M	87.1%
Q2 24	$3M	105.0%
Q3 24	$0	0.0%
Q4 24	$3M	31.0%
Q1 25	$4M	243.0%
Q2 25	$3M	172.4%
Q3 25	$0	0.0%
Q4 25	$3M	225.9%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$14M	$6M
Q2 22	$19M	$6M
Q3 22	$24M	$6M
Q4 22	$21M	$7M
Q1 23	$23M	$9M
Q2 23	$25M	$7M
Q3 23	$24M	$7M
Q4 23	$27M	$8M
Q1 24	$10M	$7M
Q2 24	$9M	$5M
Q3 24	$6M	$6M
Q4 24	$9M	$5M
Q1 25	$12M	$6M
Q2 25	$11M	$5M
Q3 25	$13M	$5M
Q4 25	$17M	$6M

Revenue Segments

Quarter	Contract research	Other revenue	License and Service	Other
Q1 22	$1M	$232.0K	—	—
Q2 22	$1M	$310.0K	—	—
Q3 22	$1M	—	$18M	$30.0K
Q4 22	$866.0K	—	$7M	$165.0K
Q1 23	$889.0K	—	$2M	—
Q2 23	$875.0K	—	$994.0K	—
Q3 23	$705.0K	—	$9M	—
Q1 24	$657.0K	—	$2M	—
Q2 24	$625.0K	—	$2M	—
Q3 24	$645.0K	—	$4M	—
Q1 25	$445.0K	—	$1M	—
Q2 25	$442.0K	—	$1M	—
Q3 25	$485.0K	—	$3M	—
Q4 25	$500.0K	—	$795.0K	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$36M	$143M	$180M
Q2 22	$68M	$180M	$249M
Q3 22	$62M	$186M	$248M
Q4 22	$45M	$172M	$218M
Q1 23	$45M	$126M	$171M
Q2 23	$31M	$89M	$120M
Q3 23	$39M	$64M	$103M
Q4 23	$40M	$79M	$119M
Q1 24	$36M	$92M	$128M
Q2 24	$23M	$88M	$111M
Q3 24	$48M	$80M	$128M
Q4 24	$25M	$89M	$114M
Q1 25	$30M	$75M	$105M
Q2 25	$25M	$74M	$100M
Q3 25	$25M	$71M	$96M
Q4 25	$20M	$71M	$91M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	61M	+0.3%	+22.0%
Q2 22	66M	+7.4%	+22.3%
Q3 22	67M	+1.0%	+8.9%
Q4 22	67M	+0.0%	+8.9%
Q1 23	67M	+0.3%	+8.9%
Q2 23	71M	+5.6%	+7.0%
Q3 23	71M	+0.2%	+6.2%
Q4 23	71M	+0.1%	+6.3%
Q1 24	71M	+0.3%	+6.3%
Q2 24	71M	+0.3%	+0.9%
Q3 24	71M	+0.1%	+0.8%
Q4 24	95M	+33.5%	+34.5%
Q1 25	122M	+28.4%	+72.2%
Q2 25	123M	+0.2%	+71.9%
Q3 25	123M	+0.0%	+71.8%
Q4 25	123M	+0.0%	+28.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$18.9K	77
Q2 22	$19.8K	77
Q3 22	$247.0K	77
Q4 22	$73.8K	105
Q1 23	$24.1K	105
Q2 23	$17.8K	105
Q3 23	$88.4K	105
Q4 23	$193.1K	91
Q1 24	$26.4K	91
Q2 24	$30.4K	91
Q3 24	$47.8K	91
Q4 24	$143.9K	64
Q1 25	$22.7K	64
Q2 25	$27.8K	64
Q3 25	$51.5K	64
Q4 25	$17.7K	73

Revenue / Employee